On April 26, 2022 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, reported that it will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm ET to report its financial results for the first quarter of 2022 (Press release, Infinity Pharmaceuticals, APR 26, 2022, View Source [SID1234612971]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity’s website at View Source and will be available on Infinity’s website for 30 days following the event.